Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc (RPRX) officer Terrance Coyne reported a proposed sale of 34,791 common shares, with an aggregate market value of $1,723,546.14 and an approximate sale date of April 28, 2026. The shares are allocated as 32,916 by TPC RP 2021 LLC and 1,875 by TPC RP EPA1 LLC. The notice states that the sales are made in connection with a selling plan dated August 8, 2025, intended to comply with Rule 10b5-1(c).
Royalty Pharma plc highlights positive Phase 3 results from partner Revolution Medicines’ RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The study met all primary and key secondary endpoints, including progression-free and overall survival, and Revolution Medicines plans to submit the data to global regulators, including a future U.S. FDA New Drug Application.
These results activate the second $250 million tranche under a previously announced $2 billion funding deal between the companies, bringing Royalty Pharma’s funding to $500 million so far. Royalty Pharma is now entitled to tiered royalties of 4.55% on daraxonrasib (and certain zoldonrasib sales), with potential step-ups to as high as 7.80% on lower sales tiers if Revolution Medicines draws the remaining synthetic royalty funding, alongside access to a senior secured term loan facility of up to $750 million linked to FDA approval and future sales milestones.
Royalty Pharma plc is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Items include electing nine directors, advisory votes on U.S. and U.K. executive pay, auditor ratifications, authority to repurchase Class A shares, and approvals to allot shares with and without pre-emption rights.
The company highlights 2025 performance with $3.3BN in portfolio receipts, $3.0BN in adjusted EBITDA, $2.7BN in portfolio cash flow, and $4.7BN in announced transaction value. It returned over $1.7BN to shareholders, including more than $1.2BN of buybacks, while deploying $2.6BN into royalty acquisitions.
Royalty Pharma completed internalization of its external manager, emphasizing stronger board oversight of compensation and succession. The largely independent, skills-diverse board—led by Chairman and CEO Pablo Legorreta and Lead Independent Director Ted Love—stresses pay-for-performance, robust share ownership guidelines, risk oversight, and corporate responsibility initiatives around responsible investment, human capital, and sustainability.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.
Royalty Pharma plc’s notice reports a planned sale of 34,791 common shares, with an aggregate market value of $1,687,015.59. The shares are for the account of Terrance Coyne, an officer, and the named selling entities are TPC RP 2021 LLC (32,916 shares) and TPC RP EPA1 LLC (1,875 shares).
The sales are in connection with a selling plan dated August 8, 2025, intended to comply with Rule 10b5-1(c). The approximate sale date is April 1, 2026, and Goldman Sachs & Co. LLC is listed as broker.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.
Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company. On March 23, 2026, TPC RP 2021, LLC sold 32,916 shares and TPC RP EPA1 LLC sold 1,875 shares in open-market transactions at a weighted average price of $45.5287 per share, with individual prices ranging from $45.30 to $45.94.
All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP 2021, LLC held 65,832 shares and TPC RP EPA1 LLC held 43,886 shares, and Coyne also reported additional indirect and direct holdings through various IRA and family accounts.
Royalty Pharma plc officer Terrance Coyne is named in a proposed sale of 34,791 common shares, with an approximate sale date of March 23, 2026. The shares are to be sold by TPC RP 2021 LLC (32,916 shares) and TPC RP EPA1 LLC (1,875 shares) under a selling plan dated August 8, 2025, intended to comply with Rule 10b5-1(c).
George Lloyd, an officer of Royalty Pharma plc, reported a proposed sale of 36,518 common shares by George Lloyd Roth IRA, with an aggregate market value of $1,662,664.54 and an approximate sale date of March 19, 2026. The proposed sale is connected to a selling plan dated August 20, 2025, intended to comply with Rule 10b5-1(c).